EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema
LONDON & NEW YORK--(BUSINESS WIRE)--Jun 14, 2023--
Stay updated with breaking news from Jonathan Prenner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LONDON & NEW YORK--(BUSINESS WIRE)--Jun 14, 2023--
Additions to EyeBio's leadership team include world-class disruptors with deep experience addressing urgent unmet needs in treatment of eye diseases - EyeBio co-founder Anthony P. Adamis, M.D., appointed
Leaders in ophthalmology drug development launch new global company to build and advance diversified portfolio of ocular therapies Eyebiotech Limited (EyeBio), a privately held ophthalmology biotechnology
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
The Fifth Annual Retina Fellow Summit This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. 2.00 CME Activity Expiration Date: 12/31/2021 Activity Overview This activity features highlights captured from the Fifth Annual Retina Fellow Summit held in November 2020. The Summit included an expert faculty panel and an audience of retina fellows engaging in discussions on current clinical data, clinical cases, and practice transitions. The overall goal of this program is to provide retina fellows, ophthalmology residents, retina ...